Ralf U Trappe
Overview
Explore the profile of Ralf U Trappe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allen U, LHuillier A, Bollard C, Gross T, Hayashi R, Hocker B, et al.
Pediatr Transplant
. 2024 May;
28(5):e14781.
PMID: 38808744
The International Pediatric Transplant Association convened an expert consensus conference to assess current evidence and develop recommendations for various aspects of care relating to post-transplant lymphoproliferative disorders (PTLD) after pediatric...
2.
Preiksaitis J, Allen U, Bollard C, Dharnidharka V, Dulek D, Green M, et al.
Pediatr Transplant
. 2023 Jun;
28(1):e14471.
PMID: 37294621
The International Pediatric Transplant Association convened an expert consensus conference to assess current evidence and develop recommendations for various aspects of care relating to post-transplant lymphoproliferative disorders after solid organ...
3.
Chaganti S, Barlev A, Caillard S, Choquet S, Cwynarski K, Friedetzky A, et al.
Adv Ther
. 2023 Jan;
40(3):1267-1281.
PMID: 36681739
Introduction: Following hematopoietic stem cell transplantation or solid organ transplantation, patients are at risk of developing Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV PTLD), which is an ultra-rare and potentially lethal...
4.
Green M, Squires J, Chinnock R, Comoli P, Danziger-Isakov L, Dulek D, et al.
Pediatr Transplant
. 2022 Nov;
28(1):e14350.
PMID: 36369745
The International Pediatric Transplant Association (IPTA) convened an expert consensus conference to assess current evidence and develop recommendations for various aspects of care relating to post-transplant lymphoproliferative disorder after solid...
5.
Sen A, Enriquez J, Rao M, Glass M, Balachandran Y, Syed S, et al.
Front Immunol
. 2022 Oct;
13:994552.
PMID: 36304469
Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation. Predisposing factors include primary Epstein-Barr virus (EBV) infection, reactivation of EBV in recipient B cells, and decreased T...
6.
Zimmermann H, Koenecke C, Dreyling M, Pott C, Duhrsen U, Hahn D, et al.
Leukemia
. 2022 Aug;
36(10):2468-2478.
PMID: 35974101
The prospective multicentre Phase II PTLD-2 trial (NCT02042391) tested modified risk-stratification in adult SOT recipients with CD20-positive PTLD based on principles established in the PTLD-1 trials: sequential treatment and risk-stratification....
7.
Zimmermann H, Nitsche M, Pott C, Reinke P, Babel N, Hermann R, et al.
Ann Hematol
. 2021 May;
100(8):2043-2050.
PMID: 33973053
Post-transplant lymphoproliferative disorders (PTLD) exclusively affecting the central nervous system-primary CNS-PTLD (pCNS-PTLD)-are rare. There is no standard therapy, and previous case series have included heterogeneous treatment approaches. We performed a...
8.
Zimmermann H, Babel N, Dierickx D, Morschhauser F, Mollee P, Zaucha J, et al.
Transplantation
. 2018 May;
102(11):1914-1923.
PMID: 29757894
Background: Current guideline recommendations for immunosuppression reduction after diagnosis of posttransplant lymphoproliferative disorder (PTLD) include stopping antimetabolites, reducing calcineurin inhibitors, and maintaining corticosteroids. However, the effect of immunosuppression on PTLD...
9.
Zimmermann H, Denecke T, Dreyling M, Franzius C, Reinke P, Subklewe M, et al.
Transplantation
. 2017 Dec;
102(5):868-875.
PMID: 29189632
Background: Fluorine-18 fluorodeoxyglucose (18F-FDG)-positron emission tomography (PET) is a recommended standard in the staging and response assessment of 18F-FDG-avid lymphoma. Posttransplant lymphoproliferative disorder (PTLD) can be detected by 18F-FDG-PET at...
10.
Trappe R, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha J, et al.
J Clin Oncol
. 2016 Dec;
35(5):536-543.
PMID: 27992268
Purpose The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial ( ClinicalTrials.gov identifier, NCT01458548) established sequential treatment with four cycles of rituximab followed by four cycles of cyclophosphamide, doxorubicin,...